AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11160548 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 16
Study 11160548 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 16
Study 11160548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread
Number of subjects: 16
Study 9787605 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine immediately after randomisation
Number of subjects: 0
Study 9787605 — intervention group
Group type: COMPARATOR
Intervention: Placebo until condition deteriorates (Control)
Number of subjects: 0
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25%, 0.5%, 0.75% and 1%)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%, 0.5% and 0.75%)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with adrenaline (5 ug.ml‐1)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (5 ug.ml‐1)
Number of subjects: 10
Study 8067217 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (plain solutions)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (plain solutions)
Number of subjects: 10
Study 8067217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and bupivacaine with adrenaline
Number of subjects: 10
Study 3394912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:200,000
Number of subjects: 38
Study 3394912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 1:200,000
Number of subjects: 38
Study 3394912 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 38
Study 31301451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8)
Number of subjects: 22
Study 31301451 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study 30115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum cardiovascular health (CVH) status
Number of subjects: 3487
Study 30115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal physical activity
Number of subjects: 3487
Study 30115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 3487
Study 30115933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 3487
Study 28655086 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT‐Ⅱ video laryngoscope
Number of subjects: 90
Study 28655086 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 90
Study 25616438 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA supplementation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Number of subjects: 0
Study 25616438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24169736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-based exercise therapy (1 hour)
Number of subjects: 30
Study 21958585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg, 2 single intravenous injections, 28 days apart)
Number of subjects: 30
Study 21958585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18986283 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antimicrobial treatment for mild CAP
Number of subjects: 0
Study 18986283 — intervention group
Group type: COMPARATOR
Intervention: Ineffective therapies or no therapy
Number of subjects: 0
Study 18986283 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome assessments
Number of subjects: 0
Study 15118778 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Number of subjects: 50
Study 15118778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 50
Study 15118778 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 11449032 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of methylphenidate (MPH)
Number of subjects: 16
Study 11449032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9554249 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 6-10, and 0.70 mg norethindrone only on days 11-19. Placebo on days 1-5 and 20-28.
Number of subjects: 10
Study 9554249 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 8-12, and 0.70 mg norethindrone only on days 13-21. Placebo on days 1-7 and 22-28.
Number of subjects: 10
Study 9554249 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1 and 2)
Number of subjects: 10
Study 8046139 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting the masker to both ears and signal to one ear
Number of subjects: 0
Study 8046139 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing different masker samples sequentially in each interval of every trial
Number of subjects: 0
Study 8046139 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting the signal in alternate bursts of multiple, identical masker samples
Number of subjects: 0
Study 2977393 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg amlodipine
Number of subjects: 12
Study 2977393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 12
Study 2977393 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amlodipine
Number of subjects: 12
Study 29273269 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alternate days on days 7-25)
Number of subjects: 364
Study 29273269 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg oral capsules, four times daily on days 1-10)
Number of subjects: 364
Study 29273269 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin
Number of subjects: 364
Study 29273269 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 364
Study 26649741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2000 mg and Avibactam 500 mg
Number of subjects: 16
Study 26649741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24739875 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 32
Study 24739875 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 32
Study 23169194 — intervention group
Group type: EXPERIMENTAL
Intervention: Verified prescription using probe‐microphone measurement
Number of subjects: 22
Study 23169194 — intervention group
Group type: COMPARATOR
Intervention: Initial-fit approach
Number of subjects: 22
Study 23169194 — intervention group
Group type: EXPERIMENTAL
Intervention: Verified prescription
Number of subjects: 22
Study 20089954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25 mg
Number of subjects: 1292
Study 20089954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 0.5 mg
Number of subjects: 1292
Study 20089954 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular interferon beta-1a
Number of subjects: 1292
Study 20089954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 1292
Study 20089954 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of disability
Number of subjects: 1292
Study 18931224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (30,000 IU IV over 4 days)
Number of subjects: 81
Study 18931224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18931224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin
Number of subjects: 81
Study 16128153 — intervention group
Group type: EXPERIMENTAL
Intervention: Old/new ERP effect for words
Number of subjects: 74
Study 16128153 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography differences in activation
Number of subjects: 74
Study 16128153 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic versus non-semantic processing
Number of subjects: 74
Study 11495875 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of intrathecal ropivacaine (group R)
Number of subjects: 36
Study 11495875 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg ropivacaine with 10 microg of sufentanil (group RS)
Number of subjects: 36
Study 11495875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 9759744 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily for 1 week)
Number of subjects: 285
Study 9759744 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (omeprazole with placebo antibiotics)
Number of subjects: 285
Study 9759744 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 285
Study 9759744 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 285
Study 8166097 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation (WF)
Number of subjects: 20
Study 8166097 — intervention group
Group type: COMPARATOR
Intervention: Rigid fixation (RIF)
Number of subjects: 20
Study 3139337 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day
Number of subjects: 30
Study 3139337 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 micrograms iodide/day
Number of subjects: 30
Study 3139337 — intervention group
Group type: EXPERIMENTAL
Intervention: 4500 micrograms iodide/day
Number of subjects: 30
Study 3139337 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 micrograms iodide/day and 4500 micrograms iodide/day
Number of subjects: 30
Study 3139337 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 30
Study 30630361 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Simvastatin
Number of subjects: 0
Study 30630361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Number of subjects: 0
Study 30630361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 0
Study 28473006 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermemories Swimming Club aquatic exercise program (12 weeks, twice weekly)
Number of subjects: 56
Study 28473006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 25979100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 29
Study 25979100 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (HF self-management with sleep hygiene)
Number of subjects: 29
Study 23580069 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost arm
Number of subjects: 688
Study 23580069 — intervention group
Group type: COMPARATOR
Intervention: No boost arm
Number of subjects: 688
Study 20926529 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.64 mg/d)
Number of subjects: 30
Study 20926529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19365011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg pegaptanib sodium
Number of subjects: 65
Study 19365011 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg pegaptanib sodium
Number of subjects: 65
Study 19365011 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 65
Study 16919571 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice MSCT
Number of subjects: 40
Study 16919571 — intervention group
Group type: COMPARATOR
Intervention: 2D echocardiography
Number of subjects: 40
Study 15589022 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential shock waveform at 200 J for patients weighing <90 kg
Number of subjects: 120
Study 15589022 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential shock waveform at 360 J for patients weighing >=90 kg
Number of subjects: 120
Study 11264907 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24
Study 11264907 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 24
Study 9146855 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (600 micrograms)
Number of subjects: 8
Study 9146855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7711007 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (100 g in 400 ml) administered 30 min before tests
Number of subjects: 0
Study 7711007 — intervention group
Group type: COMPARATOR
Intervention: Water (equal volume to glucose) administered 30 min before tests
Number of subjects: 0
Study 31780018 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 58
Study 30538005 — intervention group
Group type: EXPERIMENTAL
Intervention: rs805305 SNP of DDAH2
Number of subjects: 286
Study 30538005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak ADMA concentration
Number of subjects: 286
Study 30538005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced DDAH activity (elevated ADMA:SDMA ratio)
Number of subjects: 286
Study 30538005 — intervention group
Group type: EXPERIMENTAL
Intervention: G:G genotype
Number of subjects: 286
Study 26683126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of Platelet-Rich Plasma (PRP)
Number of subjects: 250
Study 26683126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP/PPP)
Number of subjects: 250
Study 25439692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once-daily
Number of subjects: 720
Study 25439692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 23044290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine infusion at a rate of 0.2 µg×kg(‐1)×min(‐1) from 12 hours before to 12 hours after coronary angiography or angioplasty
Number of subjects: 260
Study 23044290 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride infusion (control group)
Number of subjects: 260
Study 23044290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine infusion
Number of subjects: 260
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with AMAC stop rule instruction
Number of subjects: 62
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with AMAC stop rule instruction
Number of subjects: 62
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with FLDC stop rule instruction
Number of subjects: 62
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with FLDC stop rule instruction
Number of subjects: 62
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: AMAC stop rule instruction
Number of subjects: 62
Study 19665908 — intervention group
Group type: EXPERIMENTAL
Intervention: FLDC stop rule instruction
Number of subjects: 62
Study 18839224 — intervention group
Group type: EXPERIMENTAL
Intervention: MESNA (Uromixetan MESNA, 50 mg/ml)
Number of subjects: 30
Study 18839224 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 30
Study 16644299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 14
Study 16644299 — intervention group
Group type: COMPARATOR
Intervention: Untreated OI patients
Number of subjects: 14
Study 14500050 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (initially allocated in a 1:1 ratio)
Number of subjects: 0
Study 14500050 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (initially allocated in a 1:1 ratio)
Number of subjects: 0
Study 14500050 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential design
Number of subjects: 0
Study 14500050 — intervention group
Group type: COMPARATOR
Intervention: Nonadaptive design
Number of subjects: 0
Study 10813582 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk from allergic mothers
Number of subjects: 48
Study 10813582 — intervention group
Group type: COMPARATOR
Intervention: Breast milk from nonallergic mothers
Number of subjects: 48
Study 10813582 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk samples (colostrum and mature milk)
Number of subjects: 48
Study 8800482 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% monosodium glutamate (MSG) added to vegetable and starch dishes
Number of subjects: 31
Study 8800482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MSG)
Number of subjects: 31
Study 1310103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (EP) for 12 weeks
Number of subjects: 437
Study 1310103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and vincristine (CAV) for 18 weeks
Number of subjects: 437
Study 1310103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternation of CAV and EP (CAV/EP) for 18 weeks
Number of subjects: 437
Study 6701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiotherapy
Number of subjects: 108
Study 6701925 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose irradiation and subsequent simultaneous combination of polychemotherapy and irradiation
Number of subjects: 108
Study 6701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 108
Study 6701925 — intervention group
Group type: COMPARATOR
Intervention: Both groups of randomization
Number of subjects: 108
Study 31479804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound with 1-hour incubation time
Number of subjects: 15
Study 31479804 — intervention group
Group type: COMPARATOR
Intervention: Conventional MAL-PDT
Number of subjects: 15
Study 31479804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound
Number of subjects: 15
Study 29266675 — intervention group
Group type: EXPERIMENTAL
Intervention: E5/S100
Number of subjects: 1233
Study 29266675 — intervention group
Group type: EXPERIMENTAL
Intervention: E15/S100
Number of subjects: 1233
Study 29266675 — intervention group
Group type: COMPARATOR
Intervention: E5
Number of subjects: 1233
Study 29266675 — intervention group
Group type: COMPARATOR
Intervention: E15
Number of subjects: 1233
Study 29266675 — intervention group
Group type: COMPARATOR
Intervention: S100
Number of subjects: 1233
Study 29266675 — intervention group
Group type: EXPERIMENTAL
Intervention: E5/S100 and E15/S100
Number of subjects: 1233
Study 26850706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 763
Study 24463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Artistic gymnasts
Number of subjects: 24
Study 24463426 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study 24463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants (14-20 years)
Number of subjects: 24
Study 24463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants (7-13 years)
Number of subjects: 24
Study 22329861 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical debridement (SD)
Number of subjects: 21
Study 22329861 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical debridement (NSD)
Number of subjects: 21
Study 20657150 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva
Number of subjects: 60
Study 20657150 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood
Number of subjects: 60
Study 20657150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Number of subjects: 60
Study 20657150 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 17170047 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilled cycling training
Number of subjects: 23
Study 17170047 — intervention group
Group type: COMPARATOR
Intervention: Non-skilled cycling training
Number of subjects: 23
Study 15296815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary least squares (OLS) estimator without adjusting for measurement error
Number of subjects: 30
Study 15296815 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error
Number of subjects: 30
Study 12474066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 mL daily for 8 weeks)
Number of subjects: 50
Study 12474066 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 50
Study 9841956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate solution (0.3 g x kg‐1 body mass)
Number of subjects: 12
Study 9841956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 22
Study 7806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg
Number of subjects: 22
Study 7806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg
Number of subjects: 22
Study 7806684 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (all doses)
Number of subjects: 22
Study 2760092 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair and augmentation of the anterior cruciate ligament with a strip of the iliotibial band
Number of subjects: 111
Study 2760092 — intervention group
Group type: COMPARATOR
Intervention: Simple repair of all injured structures
Number of subjects: 111
Study 2760092 — intervention group
Group type: COMPARATOR
Intervention: Repair of all injured structures except the anterior cruciate ligament
Number of subjects: 111
Study 67592 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon thyrocalcitonin 80 u/day for three months
Number of subjects: 46
Study 67592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30547421 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐directed mask exposure/shaping practice at least once on the day of surgery (Group 2)
Number of subjects: 110
Study 30547421 — intervention group
Group type: COMPARATOR
Intervention: No exposure prior to induction (Group 3)
Number of subjects: 110